What JW Medical Systems does

JW Medical Systems (吉威医疗) is a China-based interventional cardiovascular medical device manufacturer founded in 2003 in Weihai, Shandong Province, and operating as a wholly-owned subsidiary of Blue Sail Medical (蓝帆医疗, 002382.SZ, Shenzhen Stock Exchange) following Blue Sail's 2018 acquisition of Biosensors International Group. The company designs, manufactures, and commercializes drug-eluting coronary stents (DES), drug-coated balloons (DCB), balloon catheters, and microcatheters used in percutaneous coronary intervention procedures. Its core technology stack includes a proprietary BA9 rapamycin derivative drug, a biodegradable polymer coating system, and a cobalt-chromium alloy stent platform (EXCROSSAL/心跃). JW Medical launched China's first domestically developed biodegradable polymer DES (EXCEL/爱克塞尔) in 2005 and continues to expand into adjacent interventional categories including neurovascular balloons, peripheral vascular balloons, and (via the NVT AG acquisition) structural heart devices.

The company's revenue model is hardware sales of Class III medical devices sold through B2B hospital procurement on quotation-based, multi-year contracts, distributed via direct field sales teams in Beijing, Shanghai, Guangzhou, and Xi'an supplemented by regional distributor networks. End customers are hospitals with cardiac catheterization labs and interventional cardiology departments; the marketing engine is built around academic medical conferences (CIT, Great Wall, OCC), the JCIC physician education platform, and clinical-trial-driven KOL engagement. JW Medical holds multiple NMPA Class III approvals, CE certification, ISO 9001/13485, GMP certification, and High-tech Enterprise designation, with EXCEL technology having received the State Technological Invention Award (Second Class) from the State Council in 2011.

Post-2018, under Blue Sail Medical ownership, the company has executed a series of expansion moves: the 2019 NVT AG acquisition for structural heart entry, the 2021 minority investment in Nanjing Wofuman Medical Technology for OCT imaging, the 2020-2021 buildout of a Shanghai R&D center and RMB 500M Shanghai commercial subsidiary, and a 2021-2022 wave of NMPA approvals expanding the portfolio into peripheral, neurointerventional, and drug-coated balloon categories. The company employs approximately 1,000 people and operates from a 30,000 sqm Weihai manufacturing base, with 1.5 million+ cumulative patients treated across its product lines.

Name

JW Medical Systems

Legal name

山东吉威医疗制品有限公司

Website

https://jwmedical.com.cn

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

JW Medical Systems (吉威医疗) is a China-based interventional cardiovascular medical device manufacturer and wholly-owned subsidiary of Blue Sail Medical (002382.SZ), developing and commercializing drug-eluting coronary stents, drug-coated balloons, and microcatheters for hospitals and cardiac intervention centers across China.

Ownership category

akta.pro rank

Product category

Interventional Cardiology Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

akta.pro secondary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Drug-eluting stents
• Interventional cardiology
• Balloon catheters
• Coronary stents
• Microcatheters

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales: Sales of interventional cardiology products including coronary stents, drug-eluting stents, balloon catheters, and micro-catheters to hospitals

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

JW Medical Systems is a medical device company that researches, develops, manufactures, and markets high-tech interventional cardiology products. Its portfolio spans drug-eluting coronary stents (EXCEL, EXCROSSAL 心跃, 心阔 Expansal, BioFreedom), BA9 drug-coated balloons (柏腾), microcatheters (心途), and specialty balloon catheters for neuro (畅远) and peripheral (速脉) interventions. Products are sold to hospitals and cardiac intervention centers primarily in China for the percutaneous treatment of coronary artery disease and related vascular conditions.

Differentiator

Problem solved

Functional benefit

Brands

• JCIC (吉威医疗心脏介入俱乐部): Non-commercial academic brand providing PCI intervention treatment academic services for cardiovascular doctors in China
• EXCEL (爱克塞尔)
• EXCROSSAL (心跃)
• BioFreedom
• 柏腾 (BA9 DCB)
• 心途 (Xintu)
• 畅远 (Changyuan)
• 速脉 (Sumai)

Products and services

• EXCROSSAL 心跃 Drug-Eluting Stent System Next-generation cobalt-chromium alloy biodegradable polymer-coated rapamycin-eluting coronary stent system for percutaneous coronary intervention, with reduced drug dosage and improved deliverability for treating coronary artery disease.
• EXCEL 爱克塞尔 Drug-Eluting Stent System First-generation biodegradable polymer-coated sirolimus-eluting coronary stent system; China's first domestically developed biodegradable polymer DES for the treatment of coronary artery disease.
• BioFreedom Polymer-Free Drug-Coated Stent Polymer-free BA9 drug-coated coronary stent system designed for high bleeding risk (HBR) patients, enabling shortened 1-month dual antiplatelet therapy (DAPT) protocols.
• 心阔 Expansal Cobalt-Chromium Biodegradable Polymer Sirolimus-Eluting Coronary Stent System Cobalt-chromium alloy biodegradable polymer sirolimus-eluting coronary stent system for percutaneous coronary intervention procedures.
• 柏腾 BA9 Drug-Coated Balloon Catheter (BA9 DCB) Sirolimus-derivative (BA9) drug-coated balloon catheter for the treatment of in-stent restenosis (ISR) and small vessel coronary disease, indicated for percutaneous coronary intervention.
• 心途 Xintu Microcatheter Microcatheter for use in chronic total occlusion (CTO), severe tortuosity, bifurcation lesions, and severe calcification procedures to enhance guidewire support or exchange during complex PCI.
• 畅远 Intracranial Balloon Dilatation Catheter Intracranial balloon dilatation catheter for neurointerventional procedures treating intracranial artery stenosis, including 1.0mm diameter and 5mm length specifications.
• 速脉 Sumai Peripheral Balloon Dilatation Catheter Peripheral balloon dilatation catheter for peripheral vascular system percutaneous transluminal angioplasty (PTA) and treatment of dialysis AV fistula occlusive lesions.
• POWERLINE Coronary Balloon Catheter Coronary balloon catheter within the JW Medical coronary interventional product portfolio, used in percutaneous coronary intervention procedures.
• RISE NC Non-Compliant Coronary Balloon Catheter Non-compliant (NC) coronary balloon catheter within the JW Medical coronary interventional product portfolio for high-pressure lesion preparation and stent deployment.
• 心迅 Exspeed Coronary Balloon Catheter Coronary balloon catheter within the JW Medical coronary interventional product portfolio for use in percutaneous coronary intervention procedures.
• 心迅 NC Exspeed NC Coronary Balloon Catheter Non-compliant coronary balloon catheter within the JW Medical coronary interventional product portfolio for lesion preparation and post-dilation in PCI procedures.

Quantifiable outcome

• State Technological Invention Award for EXCEL stent technology
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Biosensors International Group (柏盛国际集团)coreStrategic or Co-development PartnerBiosensors International Group is the original parent company of JW Medical Systems. The group specializes in interventional cardiovascular medical devices and has manufacturing facilities in Singapore and China. JW Medical serves as the China operations of Biosensors.
• 爱佑慈善基金会minorOthersCharity partnership for the '爱佑童心' (Aiyou Children's Heart) program, providing medical assistance to children with congenital heart disease through JW Medical's products.
• 河北医科大学第一医院minorOthersCharity medical partnership with Hebei Medical University First Hospital for clinical research and medical assistance programs.
• Nanjing Wofuman Medical Technology (南京沃福曼医疗科技有限公司)coreStrategic or Co-development PartnerJW Medical made a strategic investment in Nanjing Wofuman Medical Technology, a company specializing in OCT (Optical Coherence Tomography) imaging technology for cardiovascular interventions, expanding JW Medical's imaging capabilities.
• NVT AG (Switzerland)coreStrategic or Co-development PartnerAcquired NVT AG, a Swiss company specializing in structural heart disease products, expanding JW Medical's product portfolio beyond coronary stents into the growing structural heart disease market.

Scale indicators3 records

Recent moves12 records

Expansion highlights6 records

Broad incumbents

• B. Braun Melsungen: German medical device and pharmaceutical company with Coroflex DES and interventional cardiology offerings. Competes in adjacent geographies and certain European hospital channels alongside JW Medical's CE-certified products.
• Abbott Vascular: Global interventional cardiology market leader with Xience/XIENCE Sierra DES, balloons, and structural heart devices. Competes directly with JW Medical in Chinese tertiary hospitals and globally via broader portfolio.
• Medtronic: Global medical device leader with Resolute/Onyx DES and broad interventional cardiology, structural heart, and peripheral offerings. A direct multinational competitor in the Chinese DES market.
• Boston Scientific: Global interventional cardiology leader with Synergy/Promus DES and a broad peripheral and structural heart portfolio. Competes against JW Medical's DES offerings in Chinese hospitals and international markets.

Direct peers

• Terumo Corporation: Japanese interventional cardiology player with Ultimaster DES and a broad coronary/interventional portfolio. Comparable to JW Medical in DES technology positioning and hospital channels, especially across Asia.
• Lepu Medical Technology: Chinese medical device company with Partner and Nano+ DES franchises and a broad interventional cardiology portfolio. Comparable to JW Medical across coronary stents, balloons, and OEM/domestic hospital channels in China.
• MicroPort Scientific Corporation: Leading Chinese interventional cardiology and orthopedic device company with the Firehawk biodegradable polymer DES and broad coronary/interventional portfolio. Directly comparable to JW Medical as a domestic DES competitor serving Chinese hospitals.

Emerging players

• Sahajanand Medical Technologies: Indian DES manufacturer with Supraflex and Yukon Choice franchises expanding into European and emerging markets. Comparable to JW Medical as a non-multinational DES specialist competing on biodegradable polymer technology.
• Translumina Therapeutics: Indian DES manufacturer with Xience-like and biodegradable polymer DES offerings focused on value-tier markets. Comparable to JW Medical as an emerging-market DES competitor with overlapping product classes.

Regional players

• Nipro Corporation: Japanese medical device and pharmaceutical group with coronary stents and balloons, with stronger Japan/APAC distribution than in China. Comparable to JW Medical in interventional cardiology product breadth across Asian markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JW Medical Systems